Laura M Jacobsen1, Kendra Vehik2, Riitta Veijola3, Katharina Warncke4, Jorma Toppari5,6, Andrea K Steck7, Patricia Gesualdo7, Beena Akolkar8, Markus Lundgren9, William A Hagopian10, Jin-Xiong She11, Marian Rewers7, Anette-G Ziegler3, Jeffrey P Krischer2, Helena Elding Larsson9, Michael J Haller1. 1. Department of Pediatrics, University of Florida, Gainesville, FL. 2. Health Informatics Institute, Morsani College of Medicine, University of South Florida, Tampa, FL. 3. PEDEGO Research Unit, Department of Pediatrics, Medical Research Center, Oulu University Hospital, University of Oulu, Oulu, Finland. 4. Institute of Diabetes Research, Helmholtz Zentrum München and Forschergruppe Diabetes e.V., Neuherberg, Germany. 5. Department of Pediatrics, Turku University Hospital, Turku, Finland. 6. Research Centre for Integrative Physiology and Pharmacology, Institute of Biomedicine, Centre for Population Health Research, University of Turku, Turku, Finland. 7. Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, CO. 8. Diabetes Division, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. 9. Department of Clinical Sciences Malmö, Lund University, Skåne University Hospital, Malmö, Sweden. 10. Pacific Northwest Research Institute, Seattle, WA. 11. Center for Biotechnology and Genomic Medicine, Medical College of Georgia, Georgia Regents University, Augusta, GA.
Abstract
OBJECTIVE: The Environmental Determinants of Diabetes in the Young (TEDDY) study is uniquely capable of investigating age-specific differences associated with type 1 diabetes. Because age is a primary driver of heterogeneity in type 1 diabetes, we sought to characterize by age metabolic derangements prior to diagnosis and clinical features associated with diabetic ketoacidosis (DKA). RESEARCH DESIGN AND METHODS: The 379 TEDDY children who developed type 1 diabetes were grouped by age at onset (0-4, 5-9, and 10-14 years; n = 142, 151, and 86, respectively) with comparisons of autoantibody profiles, HLAs, family history of diabetes, presence of DKA, symptomatology at onset, and adherence to TEDDY protocol. Time-varying analysis compared those with oral glucose tolerance test data with TEDDY children who did not progress to diabetes. RESULTS: Increasing fasting glucose (hazard ratio [HR] 1.09 [95% CI 1.04-1.14]; P = 0.0003), stimulated glucose (HR 1.50 [1.42-1.59]; P < 0.0001), fasting insulin (HR 0.89 [0.83-0.95]; P = 0.0009), and glucose-to-insulin ratio (HR 1.29 [1.16-1.43]; P < 0.0001) were associated with risk of progression to type 1 diabetes. Younger children had fewer autoantibodies with more symptoms at diagnosis. Twenty-three children (6.1%) had DKA at onset, only 1 (0.97%) of 103 with and 22 (8.0%) of 276 children without a first-degree relative (FDR) with type 1 diabetes (P = 0.008). Children with DKA were more likely to be nonadherent to study protocol (P = 0.047), with longer duration between their last TEDDY evaluation and diagnosis (median 10.2 vs. 2.0 months without DKA; P < 0.001). CONCLUSIONS: DKA at onset in TEDDY is uncommon, especially for FDRs. For those without familial risk, metabolic monitoring continues to provide a primary benefit of reduced DKA but requires regular follow-up. Clinical and laboratory features vary by age at onset, adding to the heterogeneity of type 1 diabetes.
OBJECTIVE: The Environmental Determinants of Diabetes in the Young (TEDDY) study is uniquely capable of investigating age-specific differences associated with type 1 diabetes. Because age is a primary driver of heterogeneity in type 1 diabetes, we sought to characterize by age metabolic derangements prior to diagnosis and clinical features associated with diabetic ketoacidosis (DKA). RESEARCH DESIGN AND METHODS: The 379 TEDDY children who developed type 1 diabetes were grouped by age at onset (0-4, 5-9, and 10-14 years; n = 142, 151, and 86, respectively) with comparisons of autoantibody profiles, HLAs, family history of diabetes, presence of DKA, symptomatology at onset, and adherence to TEDDY protocol. Time-varying analysis compared those with oral glucose tolerance test data with TEDDY children who did not progress to diabetes. RESULTS: Increasing fasting glucose (hazard ratio [HR] 1.09 [95% CI 1.04-1.14]; P = 0.0003), stimulated glucose (HR 1.50 [1.42-1.59]; P < 0.0001), fasting insulin (HR 0.89 [0.83-0.95]; P = 0.0009), and glucose-to-insulin ratio (HR 1.29 [1.16-1.43]; P < 0.0001) were associated with risk of progression to type 1 diabetes. Younger children had fewer autoantibodies with more symptoms at diagnosis. Twenty-three children (6.1%) had DKA at onset, only 1 (0.97%) of 103 with and 22 (8.0%) of 276 children without a first-degree relative (FDR) with type 1 diabetes (P = 0.008). Children with DKA were more likely to be nonadherent to study protocol (P = 0.047), with longer duration between their last TEDDY evaluation and diagnosis (median 10.2 vs. 2.0 months without DKA; P < 0.001). CONCLUSIONS: DKA at onset in TEDDY is uncommon, especially for FDRs. For those without familial risk, metabolic monitoring continues to provide a primary benefit of reduced DKA but requires regular follow-up. Clinical and laboratory features vary by age at onset, adding to the heterogeneity of type 1 diabetes.
Authors: Joseph I Wolfsdorf; Nicole Glaser; Michael Agus; Maria Fritsch; Ragnar Hanas; Arleta Rewers; Mark A Sperling; Ethel Codner Journal: Pediatr Diabetes Date: 2018-10 Impact factor: 4.866
Authors: Jay S Skyler; Jeffrey P Krischer; Joseph Wolfsdorf; Catherine Cowie; Jerry P Palmer; Carla Greenbaum; David Cuthbertson; Lisa E Rafkin-Mervis; H Peter Chase; Ellen Leschek Journal: Diabetes Care Date: 2005-05 Impact factor: 19.112
Authors: Carla J Greenbaum; Craig A Beam; David Boulware; Stephen E Gitelman; Peter A Gottlieb; Kevan C Herold; John M Lachin; Paula McGee; Jerry P Palmer; Mark D Pescovitz; Heidi Krause-Steinrauf; Jay S Skyler; Jay M Sosenko Journal: Diabetes Date: 2012-06-11 Impact factor: 9.337
Authors: Jay M Sosenko; Jay S Skyler; Kevan C Herold; Desmond A Schatz; Michael J Haller; Alberto Pugliese; Mario Cleves; Susan Geyer; Lisa E Rafkin; Della Matheson; Jerry P Palmer Journal: Diabetes Date: 2020-05-21 Impact factor: 9.461
Authors: Richard A Oram; William A Hagopian; Lauric A Ferrat; Kendra Vehik; Seth A Sharp; Åke Lernmark; Marian J Rewers; Jin-Xiong She; Anette-G Ziegler; Jorma Toppari; Beena Akolkar; Jeffrey P Krischer; Michael N Weedon Journal: Nat Med Date: 2020-08-07 Impact factor: 87.241